Bausch + Lomb (BLCO) Jefferies Global Healthcare Conference 2025 summary

Business performance and market positioning

• Maintained strong presence across eye health, with leadership in dry eye through Mibo launch and Xiidra acquisition.

• Achieved 5% overall growth in Q1, with lens and consumer businesses both growing at 5% constant currency.

• Surgical business outperformed with 11% growth, and daily SiHy contact lenses saw 42% growth.

• Pharma business grew 1%, with key brands Xiidra and Mibo showing sequential TRX growth.

• Market share gains in lens segment both in the U.S. and internationally.

Product launches, innovation, and pipeline

• 2024 marked the highest number of product launches in company history, driving innovation.

• Significant pipeline built across all business units, with multiple launches planned for near, mid, and long term.

• R&D investor day scheduled for November 13 to provide more pipeline details.

• Biomimetic lens clinical studies expected in the second half of 2024, leveraging existing manufacturing capacity.

• ELDEOS acquisition expected to receive approval by end of 2024 and launch in early 2026.

Market dynamics and competitive landscape

• Vision market remains durable, with mid-single digit growth trends continuing.

• INVISTA franchise returned to market after recall, with thousands of lenses implanted and positive surgeon feedback.

• Premium IOL portfolio showed significant growth, with expectations to return to pre-recall levels by year-end.

• New competitor dry eye drug seen as expanding the market rather than taking share.